Currently, there are no standard treatment and relevant exploration for solid tumors patients with NED. The study aims to explore the efficacy and safety of surufatinib combined with serplulimab and standard chemotherapy in the treatment ofadvanced solid tumors with NED, in order to provide a new treatment option for advanced solid tumors patients with NED.
Histopathologically confirmed locally advanced or metastatic unresectable ESCC, BTC, PC or GC with an abnormal NED or NE phenotype (without neuroendocrine morphologic features and positive immunohistochemical expression of at least one neuroendocrine marker (CgA, Syn));
Have at least one measurable lesion according to RECIST v1.1;
ECOG performance status: 0-1;
No previous systemic therapy;
Have uncontrolled hypertension, defined as systolic blood pressure >150 mmHg or diastolic blood pressure >90 mm Hg, while under anti-hypertension treatment;
With active bleeding or bleeding tendency;
Severe history of cardiovascular and cerebrovascular diseases;
Other malignancies diagnosed within the previous 5 years, except basal cell carcinoma or cervical carcinoma in situ after radical resection.
Single group
Surufatinib
Drug250 mg, po, qd, q3w
Serplulimab
Drug200 mg, iv, d1, q3w
standard chemotherapy
DrugDecided by PI
Progression-Free Survival (PFS)
time from first-dose to the first documented disease progression or death
Objective response rate (ORR)
the proportion of patients with complete response or partial response, using RESIST v1.1
Disease Control Rate (DCR)
the proportion of patients with complete response, partial response or stable disease, using RESIST v1.1
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
